Appels à projets H2020 "Innovative Medicines Initiative 2 - Calls 22 & 23"
p2 |
DL 29/09/2020 - 17:00 Brussels time - Closing date of calls H2020 IMI2 22 & 23
The Innovative Medicines Initiative (IMI) is launching the last Calls for proposals under the IMI2 programme, with topics on tackling cancer through artificial intelligence, antimicrobial resistance, neurodegenerative diseases, rare disease diagnosis, and more.
- Call ID: H2020-JTI-IMI2- H2020-JTI-IMI2-2020-22-single-stage
- Action Type: RIA – Research and Innovation Actions
- Restricted Call to maximise impact of IMI2 JU objectives and scientific priorities
- More details
- Call ID: H2020-JTI-IMI2-2020-23-two-stage
- Action Type: RIA – Research and Innovation Actions
- Topics on tackling cancer through artificial intelligence, antimicrobial resistance, neurodegenerative diseases, rare disease diagnosis, the return of clinical trial data to participants, and patient adherence
- More details
Topics
- Topic 2: Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance
This topic is part of IMI’s Antimicrobial Resistance (AMR) Accelerator programme.
- Topic 4: Optimal treatment for patients with solid tumours in Europe through artificial intelligence
Dealines
- Stage 1 submission deadline: 29 September 2020 (17:00 Brussels time)
- Stage 2 submission deadline: 17 March 2021 (17:00 Brussels time)
IMI2 – Call 22 & 23 webinars & recordings
Contact UCLouvain
Please, feel free to contact Ms Mahdia Abdelouahab (ADRE/RINT - Phone: +32 (0)10 47.24.80) if you need further information or plan to participate.